SEC Form 4 · accession 0001209191-17-058821
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Mosbrooker
Officer — SVP, Orphan Business Unit
Period of report
Nov 1, 2017
Accepted (ET)
Nov 2, 2017 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 1, 2017 | M | 4,435 | — | A | 5,900 | D | |
| Ordinary Shares | Nov 1, 2017 | F | 2,315 | $13.83 | D | 3,585 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Nov 1, 2017 | M | 4,435 | D | — | — | Ordinary Shares | 4,435 | 13,306 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2On November 1, 2016, the reporting person was granted an aggregate of 17,741 restricted stock units. The restricted stock units vest in four equal annual installments beginning on November 1, 2017.